Ribociclib + Dexamethasone + Everolimus
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia ALL
Conditions
Acute Lymphoblastic Leukemia ALL
Trial Timeline
Jan 30, 2019 → Oct 1, 2026
NCT ID
NCT03740334About Ribociclib + Dexamethasone + Everolimus
Ribociclib + Dexamethasone + Everolimus is a phase 1 stage product being developed by Novartis for Acute Lymphoblastic Leukemia ALL. The current trial status is active. This product is registered under clinical trial identifier NCT03740334. Target conditions include Acute Lymphoblastic Leukemia ALL.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03740334 | Phase 1 | Active |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia ALL